An interventional study of Neuromodulation NESA NXSIGNAL® device in Post-Acute COVID-19 Syndrome, Dysautonomia and Neuromodulation, sponsored by Universidad Rey Juan Carlos. Recruiting at 1 site in Spain. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-06-06.
Sponsored by Universidad Rey Juan Carlos · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Post-Acute COVID-19 Syndrome · Spain.
Among the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, this one is the 35th largest by planned enrollment of the 39 interventional ones that give a count, is one of 12 that started in 2023, is one of 31 with no phase, reaches primary completion later than 0 of the 15 other live ones, and was the 16th registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →13 of the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain are open now. Recruiting first, the newest first:
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Sites in Spain
Ages 18–65
Instituto de Investigación Biomédica de Salamanca · Sites in Spain
Ages 18+
Instituto de Investigación Sanitaria Aragón · Sites in Spain
Ages 18+
Universidad Rey Juan Carlos · Sites in Spain
Ages 18+
Hellenic Institute for the Study of Sepsis · Sites in Spain, Germany, Greece and 1 more country
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 60 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 1
First in 2021; this study’s year is marked. 12 started in 2023.
This study's planned enrollment of 24 is below the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 60 across the 39 interventional studies, 184 across the 13 observational. Of the 30 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 52 have an industry lead sponsor. The 10 most frequent:
Universidad Rey Juan Carlos is the lead sponsor of 115 studies on the registry; 25 are open to participants now.
Universidad Rey Juan Carlos has 3 studies filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Post-Acute COVID-19 Syndrome with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07530757Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaSuperCAP Program to Improve Cognition and Daily Functioning in Post-COVID-19 Condition | 2026-11 |
| NCT06928480Instituto de Investigación Sanitaria AragónEffectiveness and Acceptability of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in People With Long COVID-19. | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Objectives:
To evaluate pressure pain thresholds, fatigue scales, quality of life and sleep quality, in women with Persistent Covid (PC), pre- and post-treatment using electrotherapy and in a placebo group of PC patients.
Relevance:
This trial can be a tool for patients affected by CP who present pain and fatigue problems, insomnia or signs of imbalance of their Autonomic Nervous System. It aims to improve their rest and recovery for a better quality of life that allows them to recover their Activities of Daily Living.
We have designed the study with a commitment to placebo group treatment after completion, if positive results are obtained.
A 6-month and 1-year follow-up will be scheduled.
Secondary objectives:
To analyze the effects on quality of life, fatigue and sleep. To analyze the presence of cardiac variability and pre- and post-treatment cortisol values.
Patients and Methods:
12 patients with CP will receive 15 sessions of electrotherapy. 12 will receive a placebo.
Mechanical sensitivity pre-post, by means of an algometer, cardiac variability, cortisol levels, and other variables, will be measured by means of questionnaires.
Mechanical sensitivity to pain will be measured using an algometer (Baseline 12-0300 MMT). Patients will be instructed to report when the sensation of pressure changes to pain.
The pre-post electrotherapy treatment described above will be measured, the differences in mechanical sensitivity, pain threshold to pressure, the Pittsburg questionnaires, SF-36, MFIS and EQooL-5.
Follow-up will be done at 6 months and at one year. The study design is a triple-blind randomized controlled clinical trial. Patients who sign the consent form will be evaluated by an internist who will perform a physical examination at the clinic of the Faculty of Nursing and Physiotherapy of the Pontifical University of Salamanca (UPSA).
The sample will be randomized. 12 patients will receive treatment and 12 patients will receive a placebo. With a commitment to treat these patients in the event that positive results are obtained after the end of the study.
A biphasic microcurrent will be applied with a frequency between 1.14 Hertz and 14.29 Hertz and intensities between 0.1 and 0.9 mA.
Frequency: 2 times a week. A total of 15 sessions in 7.5 weeks. The session time with microcurrents will last 60 minutes.
.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A two-phase microcurrent with a frequency between 1.14 Hertz and 14.29 Hertz and currents between 0.1 and 0.9 mA will be applied. A total of 15 sessions in 7.5 weeks. Twice a week. The session time with microcurrents will last 60 minutes.
Device: Neuromodulation NESA NXSIGNAL® device
Microcurrent machines shall be operated in such a way that they have a light signal but do not emit current. Neither the physical therapists who place them nor the subjects will be able to distinguish current-emitting machines from placebo machines. A total of 15 sessions in 7.5 weeks. Twice a week. The session time with placebo will last 60 minutes.
Device: Neuromodulation NESA NXSIGNAL® device
Good positioning of the NXSIGNAL® device, as well as proper programming, is of vital importance for the achievement of the objective. General guidelines will be established, which should always be followed with the application of NESA microcurrents, and specific guidelines for this particular study, in order to obtain as homogeneous a sample as possible and to bring the device programming as close as possible to the objective to be pursued in the clinical trial. General guidelines for the application of XSIGNAL®. The skin should be clean, free of creams and grease, so it will be necessary to clean with alcohol or similar. The placement of the gloves and socks of the device should follow the established protocols, paying attention to the location of each semielectrode in its anatomical position. The device has a color system to determine the location of each wire. The directional electrode will be placed in the cervical area at the superficial level between C6 and C7.
Pain Pressure Threshold
Central sensitization by assessment of the Pressure Pain Threshold (PPU) in kg: Baseline 12-0300 MMT algometer at cervical C5-C6, dorsal D5-D6 and anterior tibial muscle.
Time frame: Change from Baseline Pain Pressure Threshold at 1 year
Quality of life RELATED TO HEALTH
SF-36 questionnaire
Time frame: Change from baseline quality of life related to health at 1 year
Quality of life RELATED TO HEALTH
EuroQool-5-D questionnaire
Time frame: Change from baseline quality of life related to health at 1 year
effects on fatigue
MFIS questionnaire (Modificated Fatigue Impact Scale)
Time frame: Change from Baseline fatigue at 1 year
Quality of sleep
Pittsburg questionnaire
Time frame: Change from Baseline Quality of Sleep at 1 year
cardiac variability
HRV (cardiac variability)" in ms 2. "SDNN (Standard deviation of all R-R intervals)" in ms 3. "rMSSD (Root mean square of the union of adjacent R-R intervals)" in ms
Time frame: Change from Baseline Cardiac variability at 1 year
Cortisol levels
Soma OFCII cube device in nmol/L
Time frame: Change from Baseline Cortisol level at 1 year
Plan to share: No
Start is estimated for Jun 2023; primary completion for Jun 2023, 0 months later.
Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 0 months is below that.
Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →